Reza, N.; Dubey, A.; Mahmud, N.; Austin, M.A.; Duqueney, E.; Patel, P.; Boakye, E.; Marzolf, A.; Hornsby, N.; de Feria, A.;
et al. Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. J. Clin. Med. 2025, 14, 8181.
https://doi.org/10.3390/jcm14228181
AMA Style
Reza N, Dubey A, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Marzolf A, Hornsby N, de Feria A,
et al. Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. Journal of Clinical Medicine. 2025; 14(22):8181.
https://doi.org/10.3390/jcm14228181
Chicago/Turabian Style
Reza, Nosheen, Anandkumar Dubey, Nadim Mahmud, Melissa A. Austin, Estherland Duqueney, Parth Patel, Ellen Boakye, Amy Marzolf, Nicole Hornsby, Alejandro de Feria,
and et al. 2025. "Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks" Journal of Clinical Medicine 14, no. 22: 8181.
https://doi.org/10.3390/jcm14228181
APA Style
Reza, N., Dubey, A., Mahmud, N., Austin, M. A., Duqueney, E., Patel, P., Boakye, E., Marzolf, A., Hornsby, N., de Feria, A., Carattini, T., Schuler, P., & Owens, A. T.
(2025). Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. Journal of Clinical Medicine, 14(22), 8181.
https://doi.org/10.3390/jcm14228181
